Aadi halts trial, shifts focus in bid to save cash

22 August 2024

In Los Angeles, oncology company Aadi Bioscience (Nasdaq: AADI) suffered a 4% hit to its share price on Wednesday, following news that a key trial will be scrapped.

Aadi announced the termination of its Phase II PRECISION1 trial for nab-sirolimus in patients with solid tumors featuring TSC1 or TSC2 inactivating alterations.

To extend its cash runway into at least the second half of 2026, Aadi will also pause new patient enrollment in two ongoing Phase II trials of nab-sirolimus.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK